Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges

• Lower R&D spending - The company attributed reduced operating expenses to lower research and development costs.
• Reduced restructuring charges - A decline in restructuring and impairment charges contributed to the lower net loss.
• No in-process R&D expenses - The company reported nil in-process research and development expenses in Q2 2026.

The current average analyst rating on the shares is "buy", with 2 "strong buy" or "buy" recommendations, 1 "hold" and no "sell" or "strong sell" ratings.

The average consensus recommendation for the biotechnology & medical research peer group is "buy".

Wall Street's median 12-month price target for Instil Bio, Inc. is $7.00, about 6.4% below its August 12 closing price of $7.48.

Instil Bio said its second-quarter net loss narrowed as operating expenses declined sharply year over year.